Bunge Global SA

▲ Bull Case

• ◆Viterra synergy delivery tracking announced cadence: $70M realized CY2025, $190M targeted FY26, $220M run-rate by end-2027. Q1 2026 segment Adj EBIT confirms operational leverage (Soybean +56% YoY, Softseed +138% YoY, Tropical +96% YoY), indicating integration capturing costs ahead of outer-case timeline.
• ◆Crush margins inflecting upward from cycle trough: Soybean processing gross margin normalizing from $664M Q2 2024 toward $1.3B+ CY2023 mid-cycle levels. Chinese imports at 110M MT (2025 record) and South American supply clearing into late 2026 drive self-reinforcing demand recovery supporting consensus FY26 $9.62 and FY27 $11.26 Adj EPS.
• ◆Post-Viterra scale globally unmatched and defensibly positioned: Combined entity oilseed processing capacity at structural industry ceiling exactly when Brazilian crops at 15-year highs and South American origination is swing factor for global supply. Geographic diversification (Brazil, Argentina, Black Sea, US Midwest) reduces concentration vs. legacy BG and positions company for next commodity cycle.

▼ Bear Case

• ◆Balance sheet structurally overlevered post-Viterra constraining optionality: Net debt $14.3B on ~$2.9B pro-forma Adj EBITDA = 5.0x leverage. Path to 3.0x target by end-2027 requires no divestiture slippage, zero earnings misses, and strong FCF conversion. Single-quarter miss >10% or credit downgrade (BBB → BBB-, Baa2 → Baa3) delays deleveraging 12+ months and forces dividend/buyback cuts. Interest expense elevated drag for 2–3 years.
• ◆Cycle risk material and only partially hedged: Crush margins revert to trough if RVO policy disappoints (ADM precedent: −81% crushed profit YoY FY25) or Chinese demand rolls over. CY2024 trough $7.99 adj EPS; cycle averages ~$9–10. Bull case requires sustained mid-cycle margins ($10.50+), not guaranteed. Bad harvest or policy surprise forces FY27 EPS revision down to $10 or below, compressing multiple from 11x to 9–10x → $90–100.
• ◆Earnings dilution from Viterra equity issuance (65.6M new shares, 33% dilution) not yet earned: Combined entity must grow NOPAT ≥33% to be accretive to BG standalone shareholders. Current consensus implies FY27 NOPAT growth ~23% vs. FY24 standalone ($9.19 adj EPS). Dilution only earned if FY28–29 growth accelerates or synergies exceed $220M target. If FY27 lands near $11.26, combined entity barely accretive on margin-of-safety basis.

“Consensus view (9 analysts: 5 Strong Buy / 3 Buy / 1 Hold): Viterra synergies will realize on $220M run-rate by end-2027; crush margins recover to mid-cycle sustained through FY27–28 as RVO clarifies and commodity volatility normalizes; BG deleverages to 3.0x by end-2027 enabling dividend reinstatement and buyback acceleration; FY27 consensus EPS $11.26 justified at 12–13x forward multiple = $135–145 target. Bear view (implicit in Hold rating): Viterra synergies risk deceleration due to IT integration, plant consolidation, working-capital optimization complexities. Crush margins elevated due to inventory drawdown and farmer-selling panic; revert to trough if RVO unresolved or Chinese demand disappoints. Leverage won't fall below 3.5x if earnings miss. Viterra was balance-sheet bet risking backfire if execution falters. Downside $100–110 if FY26 EPS <$8.50. Core swing factor: Market betting Viterra was strategic masterstroke (bull) vs. balance-sheet mistake (bear). Q2–Q3 2026 earnings will arbitrate debate.”

• ◆Q2 2026 Earnings (late July) — First full-quarter Viterra comparable; street modeling $1.85–$1.95 adj EPS. Pass if beat >5% → maintain $130–140 target. Fail if miss >5% → revise to $110–115.
• ◆Q3 2026 Earnings (late October) — Harvest season validation of Brazilian origination throughput and South American Grain Merch margin stabilization. Pass if segment EBIT growth >0% YoY → oversupply clearing confirmed. Fail if still negative → cycle risk realized.
• ◆US Biofuel Policy Clarity (mid-2026, June–July timeframe) — RVO mandate resolution binary catalyst. Upside: $200–300M EBIT if expanded → FY27 $11.50–12.00 consensus → $140–150 target. Downside: RVO delay → margins fade → FY27 $10.00 → $100–110.
• ◆Glencore Lockup Phase 1 Release (January–March 2027) — Glencore owns 15% with 18-month phased lockup; Phase 1 = 25% release (~15M shares). Monitor for strategic retention signaling confidence vs. aggressive monetization creating equity overhang.
• ◆FY2026 Full-Year Earnings & 2027 Guidance (February 2027) — Final year validation. Pass if FY26 Adj EPS >$9.00 and FY27 guidance ≥$11.00 → bull case intact. Fail if either misses → downgrade to Hold.

• ◆Credit Downgrade to BBB− or Baa3 (HIGH severity, medium likelihood). Trigger: Net debt/EBITDA stuck >4.5x through 2H 2026 or 2 consecutive misses >10%. Impact: −15–20% re-rating, debt cost +75bp, downside to $100–110.
• ◆RVO Policy Disappointment or Delay (HIGH severity, medium likelihood). Trigger: Mandate unresolved or reduced as of June 2026. Impact: −$200–300M EBIT if demand fades; FY27 EPS $10.00–10.50 → $100–110 target. (ADM precedent: −81% crush profit YoY FY25.)
• ◆Grain Merch Segment Continued Deterioration (MEDIUM-HIGH severity, medium-high likelihood). Trigger: South American oversupply persists; EBIT <$350M Q2–Q3 2026. Impact: Each −5% EBIT = ~−$40–50M; if trend persists, FY26 miss → −10% re-rate.
• ◆Viterra Synergy Target Miss >$30M Annually (MEDIUM severity, low-medium likelihood). Trigger: IT integration, plant consolidation, working-capital optimization complexities slow payoff. Impact: Each $30M miss = −$0.15 EPS; compounds; forces multiple compression.
• ◆Brazilian BRL Weakening >15% (MEDIUM severity, medium likelihood). Trigger: BRL breaks 5.50/USD (currently ~5.05); geopolitical or macro shock. Impact: −$50–80M near-term EBIT from FX; EPS drag ~−$0.25–0.35.